ATE213505T1 - Suppressorzellen - Google Patents

Suppressorzellen

Info

Publication number
ATE213505T1
ATE213505T1 AT92925119T AT92925119T ATE213505T1 AT E213505 T1 ATE213505 T1 AT E213505T1 AT 92925119 T AT92925119 T AT 92925119T AT 92925119 T AT92925119 T AT 92925119T AT E213505 T1 ATE213505 T1 AT E213505T1
Authority
AT
Austria
Prior art keywords
cells
phenotype
tcr alpha
alpha beta
suppressor
Prior art date
Application number
AT92925119T
Other languages
English (en)
Inventor
Samuel Strober
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE213505T1 publication Critical patent/ATE213505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cable Accessories (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
AT92925119T 1991-11-05 1992-11-05 Suppressorzellen ATE213505T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78916991A 1991-11-05 1991-11-05
US93121092A 1992-08-17 1992-08-17
PCT/US1992/009628 WO1993009234A2 (en) 1991-11-05 1992-11-05 Suppressor and progenitor cells

Publications (1)

Publication Number Publication Date
ATE213505T1 true ATE213505T1 (de) 2002-03-15

Family

ID=27120885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92925119T ATE213505T1 (de) 1991-11-05 1992-11-05 Suppressorzellen

Country Status (9)

Country Link
EP (1) EP0667904B1 (de)
JP (1) JPH06510672A (de)
AT (1) ATE213505T1 (de)
AU (1) AU665042B2 (de)
CA (1) CA2124858A1 (de)
DE (1) DE69232427T2 (de)
DK (1) DK0667904T3 (de)
ES (1) ES2173085T3 (de)
WO (1) WO1993009234A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334227D1 (de) * 1992-07-10 2008-08-14 Univ Pittsburgh Hämatopoetische "facilitatory"-zellen und ihre verwendung
WO1994027622A1 (en) * 1993-05-24 1994-12-08 The Johns Hopkins University Surrogate tolerogenesis for the development of tolerance to xenografts
US5772994A (en) * 1993-05-28 1998-06-30 The University Of Pittsburgh Hematopoietic facilitatory cells and their uses
WO1995003062A1 (en) * 1993-07-21 1995-02-02 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
CA2350692A1 (en) * 1998-10-29 2000-05-11 Cell Works Diagnostics, Inc. Multiple marker characterization of single cells
CA2316089A1 (en) * 1999-10-08 2001-04-08 Li Zhang Novel cells and molecules involved in immune regulation
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
AU2005313857A1 (en) * 2004-12-10 2006-06-15 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
US20100111980A1 (en) 2004-12-10 2010-05-06 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
EP3622960A1 (de) * 2013-02-05 2020-03-18 Celularity, Inc. Natürliche killerzellen aus plazenta

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7412987A (en) * 1986-06-12 1987-12-17 Board Of Trustees Of The Leland Stanford Junior University Immunosuppressive protein

Also Published As

Publication number Publication date
CA2124858A1 (en) 1993-05-13
DE69232427T2 (de) 2002-11-21
AU665042B2 (en) 1995-12-14
WO1993009234A2 (en) 1993-05-13
AU3130093A (en) 1993-06-07
JPH06510672A (ja) 1994-12-01
ES2173085T3 (es) 2002-10-16
WO1993009234A3 (en) 1993-08-05
EP0667904A1 (de) 1995-08-23
EP0667904B1 (de) 2002-02-20
DE69232427D1 (en) 2002-03-28
DK0667904T3 (da) 2002-06-03

Similar Documents

Publication Publication Date Title
Kögler et al. Cytokine production and hematopoiesis supporting activity of cord blood–derived unrestricted somatic stem cells
Le Blanc Immunomodulatory effects of fetal and adult mesenchymal stem cells
Machado et al. Immunological characteristics of mesenchymal stem cells
DK0667904T3 (da) Suppressor- og progenitor-celler
Kobylka et al. Preservation of immunological and colony-forming capacities of long-term (15 years) cryopreserved cord blood cells1
Wachtel et al. H–Y antigen and the origin of XY female wood lemmings (Myopus schisticolor)
ES2161875T3 (es) Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.
Almeida et al. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage− cells
Götherström Immunomodulation by multipotent mesenchymal stromal cells
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
WO2000006704A3 (en) Hematopoietic cell composition for use in transplantation
NO20001509D0 (no) Dannelse av hematopoetiske celler fra multipotente nøytrale stam-celler
Gluckman et al. Umbilical cord blood transplants
Knobel et al. Long-term reconstitution of mice after ex vivo expansion of bone marrow cells: differential activity of cultured bone marrow and enriched stem cell populations
Bartsch et al. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used
Peltzer et al. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use
Meyer‐Monard et al. Clinical‐grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation
Prather et al. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood
Mancusi et al. CD4+ FOXP3+ regulatory T cell therapies in HLA haploidentical hematopoietic transplantation
Wang et al. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming
Rugeles et al. EVIDENCE FOR THE PRESENCE OF MULTILINEAGE CHIMERISM AND PROGENITORS OF DONOR DENDRITIC CELLS IN THE PERIPHERAL BLOOD OF BONE MARROW-AUGMENTED ORGAN TRANSPLANT RECIPIENTS1
EP0765398A4 (de) Population von mit myeloid-und/oder lymphoid-vorläufern angereicherten zellen und verfahren zur ihrer gewinnung und verwendung
El-Badri et al. SUCCESSFUL PREVENTION OF AUTOIMMUNE DISEASE BY TRANSPLANTATION OF ADEQUATE NUMBER OF FULLY ALLOGENEIC HEMATOPOIETIC STEM CELLS1
Norio Isolation of spermatozoa, their ultrastructure, and their fertilizing capacity in two frogs, Rana japonica and Xenopus laevis
Kosugi-Kanaya et al. Long-lasting graft-derived donor T cells contribute to the pathogenesis of chronic graft-versus-host disease in mice

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0667904

Country of ref document: EP

REN Ceased due to non-payment of the annual fee